Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

NCT01315678 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

302

Enrollment

INDUSTRY

Sponsor class

Conditions

Pseudomonas Aeruginosa Infection

Interventions

DRUG: Liposomal amikacin for inhalation (Arikayce™) using the PARI Investigational eFlow® Nebulizer.
DRUG: Tobramycin inhalation solution using a PARI LC® Plus nebulizer.

Sponsor

Insmed Incorporated